GlassScriptPhysician profile
Paul Ryan Lane
NPI 1962023820
$4,141.34
in general payments reported to CMS, 2019-2025
26 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $749 · 2022: $1,342 · 2023: $1,117 · 2024: $427 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,161.52 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,113.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $346.19 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $233.29 | 2021-2023 | Trelegy Ellipta |
| Pfizer INC. | $212.65 | 2022-2025 | |
| Lilly USA, LLC | $205.94 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Mylan Specialty L.P. | $118.59 | 2021-2023 | Yupelri |
| Amgen INC. | $99.06 | 2021-2022 | |
| Dexcom, INC. | $89.46 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $85.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $76.59 | 2021-2023 | |
| Amarin Pharma, INC. | $69.15 | 2021 | |
| Insulet Corporation | $59.33 | 2023-2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $46.29 | 2022-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $31.07 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $25.09 | 2025 | Auvelity |
| Electromed, INC. | $22.05 | 2022 | |
| Almatica Pharma LLC | $19.30 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.91 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $17.93 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.68 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.43 | 2022 | |
| Upsher-Smith Laboratories LLC | $16.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.12 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.67 | 2021 | |
| Grifols USA, LLC | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.